



Charles M. Lizza
Phone: (973) 286-6715
Fax: (973) 286-6815
clizza@saul.com
www.saul.com

December 22, 2022

VIA ECF [REDACTED]

The Honorable Zahid N. Quraishi, U.S.D.J.
United States District Court
Clarkson S. Fisher Federal Building & U.S. Courthouse
402 E. State Street
Trenton, New Jersey 08608

Re: *Helsinn Healthcare S.A. v. Gland Pharma Limited*
Civil Action No. 22-4635 (ZNQ)(LHG)

Dear Judge Quraishi:

This firm, together with Paul Hastings LLP, represents Plaintiff Helsinn Healthcare S.A. in the above-captioned matter.

We are pleased to inform the Court that the parties have reached an amicable resolution of this matter. Accordingly, enclosed for Your Honor's consideration is a [Proposed] Consent Judgment and Dismissal Order ("Consent Judgment"), which, subject to the Court's approval, would dismiss this case. If the enclosed Consent Judgment meets with the Court's approval, we respectfully request that Your Honor sign and have it entered on the docket under seal because it contains information that Gland believes is confidential. To this end, we are also enclosing a version of the Consent Judgment that redacts this information, which can be signed by Your Honor and entered publicly on the docket. Gland will file a motion to seal in accordance with Local Civil Rule 5.3.

Thank you for Your Honor's kind attention to this matter.

Respectfully yours,

A handwritten signature in blue ink, appearing to read "Charles M. Lizza".

Charles M. Lizza

Enclosures

cc: Hon. Lois H. Goodman, U.S.M.J. (via ECF)
All Counsel (via e-mail)

UNREDACTED CONSENT JUDGMENT

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

HELSINN HEALTHCARE S.A.,

Plaintiff,

v.

GLAND PHARMA LIMITED,

Defendant.

Civil Action No. 22-4635 (ZNQ)(LHG)



(Filed electronically)

[PROPOSED] CONSENT JUDGMENT AND DISMISSAL ORDER

This action for patent infringement (the “Litigation”) has been brought by Plaintiff Helsinn Healthcare S.A. (“Helsinn”) against Defendant Gland Pharma Limited (“Gland”) for infringement of U.S. Patent Nos. 8,426,450, 8,895,586, 9,186,357, 9,403,772, 9,908,907, 10,208,073, 10,624,911, 10,717,721, 10,828,297, and 11,312,698 (the “Helsinn Patents”). Helsinn’s commencement of the Litigation was based on its receipt of notice from Gland that Gland had filed Abbreviated New Drug Application (“ANDA”) No. 217374 with the United States Food and Drug Administration (“FDA”) containing certifications pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) directed to the Helsinn Patents and seeking approval to market generic EQ 11.75 mg/mL fosnetupitant chloride hydrochloride and 0.0125 mg/mL palonosetron hydrochloride, 235 mg/0.25 mg per 20 mL single-dose vials for intravenous administration.

Helsinn and Gland have resolved this Litigation on the expectation and belief that this would eliminate the substantial litigation costs that would otherwise be incurred by both Helsinn and Gland during the Litigation, while also serving the public interest by saving judicial resources and avoiding the risks to each of the parties associated with litigation. This resolution will afford Helsinn and Gland the procompetitive opportunity to more productively use money

and other resources that would have been spent in the continued prosecution and defense of this Litigation, to the benefit of the parties and consumers alike, such as by investing more money in pharmaceutical research and development.

The Court, upon the consent and request of Helsinn and Gland, hereby acknowledges the following Consent Judgment and, upon due consideration, issues the following Dismissal Order.

Helsinn and Gland now consent to this Consent Judgment and Dismissal Order and

IT IS HEREBY ORDERED, ADJUDGED AND DECREED that:

1. Subject matter jurisdiction, personal jurisdiction, and venue solely with respect to the Litigation are all proper in this Court.

2. In this Litigation, Helsinn has charged Gland with infringement of the Helsinn Patents in connection with Gland's submission of ANDA No. 217374 directed to EQ 11.75 mg/mL fosnetupitant chloride hydrochloride and 0.0125 mg/mL palonosetron hydrochloride, 235 mg/0.25 mg per 20 mL single-dose vials for intravenous administration to the FDA.

3. In response to Helsinn's charges of patent infringement, Gland has alleged certain defenses and counterclaims. No decision has been obtained by the parties from this Court regarding these charges of infringement or these defenses and counterclaims.

4. Gland has not rebutted the statutory presumption that the Helsinn Patents are valid and enforceable in the Litigation. This admission is without prejudice to Gland's defenses and counterclaims that the Helsinn Patents are invalid.

5. Gland admits that the submission of ANDA No. 217374 containing certifications pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) to the FDA for the purpose of obtaining regulatory approval to engage in the commercial manufacture, use and/or sale of generic EQ 11.75 mg/mL fosnetupitant chloride hydrochloride and 0.0125 mg/mL palonosetron hydrochloride, 235

mg/0.25 mg per 20 mL single-dose vials for intravenous administration within the United States before the expiration of the Helsinn Patents was a technical act of infringement of the Helsinn Patents under 35 U.S.C. § 271(e)(2)(A).

6. All claims, counterclaims, and affirmative defenses presented by Helsinn as between it and Gland, or by Gland, in the Litigation are hereby dismissed without prejudice.

7. Gland, its officers, agents, servants, employees and attorneys, and those persons in active concert or participation with them shall not engage in manufacturing, using, offering to sell or selling within the United States, or importing into the United States, any generic EQ 11.75 mg/mL fosnetupitant chloride hydrochloride and 0.0125 mg/mL palonosetron hydrochloride, 235 mg/0.25 mg per 20 mL single-dose vials for intravenous administration that are the subject of ANDA No. 217374 until [REDACTED] or at such earlier date as agreed to by the Parties.

8. Helsinn and Gland each expressly waives any right to appeal from this Consent Judgment and Dismissal Order.

9. This court retains jurisdiction over Helsinn and Gland for purposes of enforcing this Consent Judgment and Dismissal Order.

10. The Clerk of the Court is directed to enter this Consent Judgment and Dismissal Order forthwith.

THE HONORABLE ZAHID N. QURAISHI, U.S.D.J.

Dated: December 22, 2022

s/ Charles M. Lizza

Charles M. Lizza
William C. Baton
Sarah A. Sullivan
Alexander L. Callo
SAUL EWING LLP
One Riverfront Plaza, Suite 1520
Newark, NJ 07102
(973) 286-6700
clizza@saul.com

Of Counsel:

Eric W. Dittmann
Melanie R. Rupert
Isaac S. Ashkenazi
Dana Weir
M. Ryan Meuth
PAUL HASTINGS LLP
200 Park Avenue
New York, NY 10166
(212) 318-6000

*Attorneys for Plaintiff
Helsinn Healthcare S.A.*

SO STIPULATED:

s/ James S. Richter

James S. Richter
MIDLIGE RICHTER LLC
645 Martinsville Road
Basking Ridge, NJ 07920
(908) 626-0622
jrichter@midlige-richter.com

Of Counsel:

Imron T. Aly
ARENTFOX SCHIFF LLP
233 S. Wacker Drive, Suite 7100
Chicago, IL 60606
(312) 258-5500
imron.aly@afslaw.com

John K. Hsu
Bradford C. Frese
Jieun Lee
ARENTFOX SCHIFF LLP
1717 K Street NW
Washington, DC 20006
(202) 857-6000
john.hsu@afslaw.com
bradford.frese@afslaw.com
ji.lee@afslaw.com

*Attorneys for Defendant
Gland Pharma Limited*

**REDACTED
CONSENT
JUDGMENT**

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

HELSINN HEALTHCARE S.A.,

Plaintiff,

v.

GLAND PHARMA LIMITED,

Defendant.

Civil Action No. 22-4635 (ZNQ)(LHG)

(Filed electronically)

[PROPOSED] CONSENT JUDGMENT AND DISMISSAL ORDER

This action for patent infringement (the “Litigation”) has been brought by Plaintiff Helsinn Healthcare S.A. (“Helsinn”) against Defendant Gland Pharma Limited (“Gland”) for infringement of U.S. Patent Nos. 8,426,450, 8,895,586, 9,186,357, 9,403,772, 9,908,907, 10,208,073, 10,624,911, 10,717,721, 10,828,297, and 11,312,698 (the “Helsinn Patents”). Helsinn’s commencement of the Litigation was based on its receipt of notice from Gland that Gland had filed Abbreviated New Drug Application (“ANDA”) No. 217374 with the United States Food and Drug Administration (“FDA”) containing certifications pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) directed to the Helsinn Patents and seeking approval to market generic EQ 11.75 mg/mL fosnetupitant chloride hydrochloride and 0.0125 mg/mL palonosetron hydrochloride, 235 mg/0.25 mg per 20 mL single-dose vials for intravenous administration.

Helsinn and Gland have resolved this Litigation on the expectation and belief that this would eliminate the substantial litigation costs that would otherwise be incurred by both Helsinn and Gland during the Litigation, while also serving the public interest by saving judicial resources and avoiding the risks to each of the parties associated with litigation. This resolution will afford Helsinn and Gland the procompetitive opportunity to more productively use money

and other resources that would have been spent in the continued prosecution and defense of this Litigation, to the benefit of the parties and consumers alike, such as by investing more money in pharmaceutical research and development.

The Court, upon the consent and request of Helsinn and Gland, hereby acknowledges the following Consent Judgment and, upon due consideration, issues the following Dismissal Order.

Helsinn and Gland now consent to this Consent Judgment and Dismissal Order and

IT IS HEREBY ORDERED, ADJUDGED AND DECREED that:

1. Subject matter jurisdiction, personal jurisdiction, and venue solely with respect to the Litigation are all proper in this Court.

2. In this Litigation, Helsinn has charged Gland with infringement of the Helsinn Patents in connection with Gland's submission of ANDA No. 217374 directed to EQ 11.75 mg/mL fosnetupitant chloride hydrochloride and 0.0125 mg/mL palonosetron hydrochloride, 235 mg/0.25 mg per 20 mL single-dose vials for intravenous administration to the FDA.

3. In response to Helsinn's charges of patent infringement, Gland has alleged certain defenses and counterclaims. No decision has been obtained by the parties from this Court regarding these charges of infringement or these defenses and counterclaims.

4. Gland has not rebutted the statutory presumption that the Helsinn Patents are valid and enforceable in the Litigation. This admission is without prejudice to Gland's defenses and counterclaims that the Helsinn Patents are invalid.

5. Gland admits that the submission of ANDA No. 217374 containing certifications pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) to the FDA for the purpose of obtaining regulatory approval to engage in the commercial manufacture, use and/or sale of generic EQ 11.75 mg/mL fosnetupitant chloride hydrochloride and 0.0125 mg/mL palonosetron hydrochloride, 235

mg/0.25 mg per 20 mL single-dose vials for intravenous administration within the United States before the expiration of the Helsinn Patents was a technical act of infringement of the Helsinn Patents under 35 U.S.C. § 271(e)(2)(A).

6. All claims, counterclaims, and affirmative defenses presented by Helsinn as between it and Gland, or by Gland, in the Litigation are hereby dismissed without prejudice.

7. Gland, its officers, agents, servants, employees and attorneys, and those persons in active concert or participation with them shall not engage in manufacturing, using, offering to sell or selling within the United States, or importing into the United States, any generic EQ 11.75 mg/mL fosnetupitant chloride hydrochloride and 0.0125 mg/mL palonosetron hydrochloride, 235 mg/0.25 mg per 20 mL single-dose vials for intravenous administration that are the subject of ANDA No. 217374 until [REDACTED] or at such earlier date as agreed to by the Parties.

8. Helsinn and Gland each expressly waives any right to appeal from this Consent Judgment and Dismissal Order.

9. This court retains jurisdiction over Helsinn and Gland for purposes of enforcing this Consent Judgment and Dismissal Order.

10. The Clerk of the Court is directed to enter this Consent Judgment and Dismissal Order forthwith.

THE HONORABLE ZAHID N. QURAISHI, U.S.D.J.

Dated: December 22, 2022

s/ Charles M. Lizza

Charles M. Lizza
William C. Baton
Sarah A. Sullivan
Alexander L. Callo
SAUL EWING LLP
One Riverfront Plaza, Suite 1520
Newark, NJ 07102
(973) 286-6700
clizza@saul.com

Of Counsel:

Eric W. Dittmann
Melanie R. Rupert
Isaac S. Ashkenazi
Dana Weir
M. Ryan Meuth
PAUL HASTINGS LLP
200 Park Avenue
New York, NY 10166
(212) 318-6000

*Attorneys for Plaintiff
Helsinn Healthcare S.A.*

SO STIPULATED:

s/ James S. Richter

James S. Richter
MIDLIGE RICHTER LLC
645 Martinsville Road
Basking Ridge, NJ 07920
(908) 626-0622
jrichter@midlige-richter.com

Of Counsel:

Imron T. Aly
ARENTFOX SCHIFF LLP
233 S. Wacker Drive, Suite 7100
Chicago, IL 60606
(312) 258-5500
imron.aly@afslaw.com

John K. Hsu
Bradford C. Frese
Jieun Lee
ARENTFOX SCHIFF LLP
1717 K Street NW
Washington, DC 20006
(202) 857-6000
john.hsu@afslaw.com
bradford.frese@afslaw.com
ji.lee@afslaw.com

*Attorneys for Defendant
Gland Pharma Limited*